Updated:
Genesis Biocapital Management
Genesis Biocapital Management is a New York–based single-family office investing exclusively in life sciences, biotech, and healthcare companies across...
Genesis Biocapital Management
Genesis Biocapital Management was founded in 2020 as a single-family office focused entirely on the life sciences sector. Its founding principal has not been publicly identified, and the wealth origin is not disclosed in public records. The firm operates from New York City. The firm targets therapeutic, diagnostic, and platform companies across all development stages, from preclinical to commercial. Its mandate spans direct equity investments, co-investments alongside specialized venture funds, and public market positions in biotech and pharma. The portfolio is concentrated in North American and European companies with what the firm describes as 'transformative science and strong intellectual property.' Confirmed holdings are not publicly reported. Team size, additional offices, and total deployment are undisclosed. No philanthropic or adjacent vehicles have been publicly linked to the firm. As of early 2025, no recent operational events (e.g., fundraising, leadership changes, or public deal announcements) have been reported. Genesis Biocapital Management's structural differentiator is its hyper-specialization — it operates as one of the few family offices explicitly dedicated only to life sciences, rather than allocating broadly. That focus implies internal scientific diligence capacity and a long investment horizon aligned with drug development timelines.
General information
Firm type
Single Family Office
Year founded
2020
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Genesis Biocapital Management?
The firm's investment principals are not publicly named. Genesis Biocapital Management does not disclose its leadership team or investment committee structure in public sources.
How does Genesis Biocapital Management source proprietary deal flow?
The firm relies on its internal network and direct outreach to biotech founders, academic researchers, and specialist venture firms. Without public deal announcements or regulatory filings, specific sourcing channels are not verifiable.
Is Genesis Biocapital Management a single-family office or does it manage outside capital?
The firm is structured as a single-family office. There is no public evidence it manages capital for external limited partners or operates pooled investment vehicles open to third parties.
What investment stages does Genesis Biocapital Management typically target?
The firm invests across the biotech lifecycle — from early-stage venture rounds (Series A/B) to public market positions in listed biotech and pharma companies. It does not publicly disclose a stage preference or minimum check size.
Which sectors does Genesis Biocapital Management explicitly avoid?
The firm limits itself exclusively to life sciences and healthcare. It does not invest in technology, real estate, energy, or other sectors common among diversified family offices.
Does Genesis Biocapital Management maintain philanthropic structures?
No philanthropic foundation, donor-advised fund, or charitable arm has been publicly linked to the family office or its principals as of mid-2025.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: